Tacrolimus population pharmacokinetics in adult heart transplant patients
British Journal of Clinical Pharmacology · 2023
DOI: 10.1111/bcp.15857 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Adrien Paschier und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Pharmacovigilance, University Hospital of Limoges, Limoges, France. Hauptthemen laut MEDLINE: Kidney Transplantation, Heart Transplantation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 37 Literaturangaben.
Abstract (Originalsprache)
Introduction
Tacrolimus is an immunosuppressant largely used in heart transplantation. However, the calculation of its exposure based on the area under the curve (AUC) requires the use of a population pharmacokinetic (PK) model. The aims of this work were (i) to develop a population PK model for tacrolimus in heart transplant patients, (ii) to derive a maximum a posteriori Bayesian estimator (MAP‐BE) based on a limited sampling strategy (LSS) and (iii) to estimate probabilities of target attainment (PTAs) for AUC and trough concentration (C0). Material and Methods Forty‐seven PK profiles (546 concentrations) of 18 heart transplant patients of the Pharmacocinétique des Immunosuppresseurs chez les patients GREffés Cardiaques study receiving tacrolimus (Prograf®) were included. The database was split into a development (80%) and a validation (20%) set. PK parameters were estimated in MONOLIX® and based on this model a Bayesian estimator using an LSS was built. Simulations were performed to calculate the PTA for AUC and C0.
Results
The best model to describe the tacrolimus PK was a two‐compartment model with a transit absorption and a linear elimination. Only the CYP3A5 covariate was kept in the final model. The derived MAP‐BE based on the LSS (0‐1‐2 h postdose) yielded an AUC bias ± SD = 2.7 ± 10.2% and an imprecision of 9.9% in comparison to the reference AUC calculated using the trapezoidal rule. PTAs based on AUC or C0 allowed new recommendations to be proposed for starting doses (0.11 mg·kg −1 ·12 h −1 for the CYP3A5 nonexpressor and 0.22 mg·kg 1 ·12 h −1 for the CYP3A5 expressor).
Conclusion
The MAP‐BE developed should facilitate estimation of tacrolimus AUC in heart transplant patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Toxicology and Pharmacovigilance, University Hospital of Limoges, Limoges, France.
- Department of Pharmacology and Toxicology, University Hospital of Nice, Nice, France.
- Pharmacology & Transplantation, INSERM U1248, Université de Limoges, Limoges, France.
- Université Côte d'Azur, Inria, CNRS, Laboratoire J.A. Dieudonné, Maasai team, Nice, France.
ORCID-Profile: Marc Labriffe, Jean-Baptiste Woillard
Zitieren
APA
Paschier, A., Destere, A., Monchaud, C., Labriffe, M., Marquet, P., & Woillard, J. B. (2023). Tacrolimus population pharmacokinetics in adult heart transplant patients. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15857
Vancouver
Paschier A, Destere A, Monchaud C, Labriffe M, Marquet P, Woillard JB. Tacrolimus population pharmacokinetics in adult heart transplant patients. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15857
BibTeX
@article{Paschier2023,
author = {Paschier, Adrien and Destere, Alexandre and Monchaud, Caroline and Labriffe, Marc and Marquet, Pierre and Woillard, Jean-Baptiste},
title = {Tacrolimus population pharmacokinetics in adult heart transplant patients},
journal = {British Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1111/bcp.15857}
}
EUVIMED